Mechanism of nuclear factor of activated T-cells mediated FasL expression in corticosterone -treated mouse Leydig tumor cells
© Chai et al; licensee BioMed Central Ltd. 2008
Received: 05 February 2008
Accepted: 12 June 2008
Published: 12 June 2008
Fas and FasL is important mediators of apoptosis. We have previously reported that the stress levels of corticosterone (CORT, glucocorticoid in rat) increase expression of Fas/FasL and activate Fas/FasL signal pathway in rat Leydig cells, which consequently leads to apoptosis. Moreover, our another study showed that nuclear factor of activated T-cells (NFAT) may play a potential role in up-regulation of FasL during CORT-treated rat Leydig cell. It is not clear yet how NFAT is involved in CORT-induced up-regulation of FasL. The aim of the present study is to investigate the molecular mechanisms of NFAT-mediated FasL expression in CORT-treated Leydig cells.
Western blot analysis showed that NFAT2 expression is present in mouse Leydig tumor cell (mLTC-1). CORT-induced increase in FasL expression in mLTC-1 was ascertained by Western Blot analysis and CORT-induced increase in apoptotic frequency of mLTC-1 cells was detected by FACS with annexin-V labeling. Confocal imaging of NFAT2-GFP in mLTC-1 showed that high level of CORT stimulated NFAT translocation from the cytoplasm to the nucleus. RNA interference-mediated knockdown of NFAT2 significantly attenuated CORT-induced up-regulation of FasL expression in mLTC. These results corroborated our previous finding that NFAT2 is involved in CORT-induced FasL expression in rat Leydig cells and showed that mLTC-1 is a suitable model for investigating the mechanism of CORT-induced FasL expression. The analysis of reporter constructs revealed that the sequence between -201 and +71 of mouse FasL gene is essential for CORT-induced FasL expression. The mutation analysis demonstrated that CORT-induced FasL expression is mediated via an NFAT binding element located in the -201 to +71 region. Co-transfection studies with an NFAT2 expression vector and reporter construct containing -201 to +71 region of FasL gene showed that NFAT2 confer a strong inducible activity to the FasL promoter at its regulatory region. In addition, chromatin immunoprecipitation assay further confirmed the results of reporter gene studies by showing the specific binding of NFAT2 to the -201 to +71 region.
In the present study, we demonstrated that NFAT2 directly stimulates transcription of FasL in high level CORT-treated mLTC-1. In conclusion, the present study provides further evidence for our finding that CORT-induced FasL expression in Leydig cells is mediated by NFAT.
Fas and its ligand FasL are a pair of trans-membrane proteins critically involved in apoptosis. Fas is expressed in many types of tissues, whereas FasL expression is more restricted . FasL expression is predominantly found in activated T cells. However, its expression is also reported in and outside of the immune system, such as NK cells, macrophages and Sertoli cells in testis [2–6].
In male mammalian, the sexual hormone testosterone is secreted by Leydig cells in testis. We have recently demonstrated that the high levels of corticosterone (CORT, glucocorticoid in rat) that are typically achieved during stress induce apoptotic death of Leydig cells and the activation of the Fas/FasL system, cleavage of procaspase-3, loss of mitochondrial membrane potential and increased ROS generation are all implicated in the process of CORT-induced Leydig cell death [7–9]. But the mechanism of FasL expression regulation in CORT-mediated Leydig cell apoptosis is unclear. Transcriptional regulation of FasL expression is a complicated process, which could be involved in a variety of transcriptional factors . It was known that FasL expression is dependent on nuclear factor of activated T-cells (NFAT) in T lymphocyte. In our another study, it was found that the expression of FasL was increased in 100 nM CORT-treated rat Leydig cells and the increased expression could be alleviated by NFAT inhibitor CsA. Meanwhile, Western blot analysis of NFAT protein in the cytoplasm and nuclei demonstrated that NFAT was activated by CORT treatment . These results indicated that NFAT is involved in CORT-induced FasL expression in Leydig cells, but the molecular basis for this process is not clear yet. Therefore, the present study is dedicated to investigate how NFAT be involved in regulation of FasL transcription.
Analysis of NFAT2 expression in Leydig cells
Assay of FasL expression in mLTC-1 cells
RNA interference-mediated silencing of NFAT2 gene
CORT-induced NFAT2-GFP nuclear translocation
Enhancement of FasL promoter activity by CORT treatment
Transfection of mLTC-1 cells with deletion constructs of FasL promoter
Transfection of mLTC-1 cells with mutant FasL promoter constructs at 272 bp sequence
Activation of FasL promoter activity with transfection of NFAT expression construct
Specific Binding of NFAT2 to the FasL promoter in vivo
Detection of CORT-induced apoptosis of mLTC-1 cells
The receptor-ligand pair of Fas and FasL mediates apoptosis in a wide variety of different cell populations. The importance of these interactions has been convincingly demonstrated in murine and humans possessing loss of function mutations in either molecule [15–18]. The biological importance of FasL has been highlighted recently by work demonstrating its critical role in both activation-induced cell death in T cells and in the maintenance of immune privilege within certain tissues [19–21]. However, relatively little is known about factors that regulate inducible expression of FasL outside of the immune system. Our previous studies established a critical role for FasL in Leydig cell via its action in CORT-induced apoptosis. We are the first to demonstrate that involvement of NFAT on regulation of FasL expression in CORT-induced Leydig cell apoptosis . But the molecular mechanisms of NFAT-mediated up-regulation of FasL expression in CORT-induced Leydig cell apoptosis are unknown. Regulation of FasL expression is a complicated process, which could be involved in a variety of trascriptional factors including NFAT, SP1, early growth response gene (Egr) and so on. The NFAT family of transcription factors is composed of four family members NFAT1, NFAT2, NFAT3 and NFAT4, and is best known for its role in the regulation of the T cell immune response [22–27]. The principal function of NFAT in T cells is to couple stimulation of the T cell antigen receptor to changes in the expression of a number of cytokine and other immunologically important genes. NFAT are regulated primarily at the level of their subcellular localization through the actions of serine/threonine phosphatase calcineurin (CaN). In resting cells, NFAT family members are normally located in the cytoplasm in a hyperphosphorylated latent form. However, following activated CaN directly dephosphorylates NFAT proteins, nuclear import and increased intrinsic DNA binding activity occur, which could be specially inhibited by CsA. Once located in the nucleus, NFAT are then free to bind to their target promoter elements and activate the transcription of specific NFAT target genes, either alone or in combination with other nuclear partners.
This aspect of NFAT regulation is likely to be significant, since both the extent and duration of NFAT activity have recently been shown to influence the qualitative pattern of NFAT-dependent gene expression induced during T cell activation . The NFAT signaling pathway is certainly best known for its role in the regulation of the immune response. The NFAT is expressed in many cell types and contributes to diverse cellular functions [22, 29–34]. Therefore, it has become increasingly apparent that this pathway also plays an important role in the regulation of a wide variety of cellular responses in a number of other tissues.
Our recent study had verified that NFAT was involved in CORT-induced expression of FasL in rat Leydig cells . Owing to relatively little is known about NFAT regulation of FasL expression outside of the immune system, no doubt, it is very interesting to observe whether NFAT regulate FasL expression through affection FasL promotor activation in CORT-treated Leydig cells.
In the present study, mLTC-1 were selected as cell model due to its suitability for transfection. Although it is widely accepted that mLTC-1 is a favorable model for study on biology of Leydig cells, we validated firstly that CORT-induced up-regulation of FasL expression is also present in mLTC-1 by RT-PCR and Western blotting analysis. Western blotting analysis showed NFAT2 is the predominant isoform in mLTC. However, other members of NFAT family, i. e. NFAT1, NFAT3 and NFAT4 exprssion is very low compared to NFAT2 in mLTC-1 (our unpublished data). It was also shown that NFAT2-GFP chimeric protein translocated from cytoplasm to nuclus after CORT treatment and siRNA-mediated silencing of NFAT decreased the extent of CORT-induced FasL expression. These results were in accord with our finding in rat Leydig cells, i.e. high level CORT activates Fas/FasL signal pathway through activation of NFAT.
Previous studies from other investigators suggested the presence of multiple elements at -689 bp at 5' untranslated region of FasL promoter, which is capable of enhancing transcriptional activity of the FasL promoter in T cells . Furthermore, we predicated the transcription start site and transcription factor binding sites on FasL promoter by analyzing the sequence of FasL 5' untranslated region through online-based computer program. Based on these messages, the -689 bp at 5' untranslated region of FasL promoter was selected as an object to observe NFAT regulation of FasL promoter activity in present study. In order to elucidate the mechanism of CORT-triggered up-regulation of FasL expression in CORT-treated Leydig cells, we cloned -689 bp (-618- +71) at 5' untranslated region of FasL promoter and found that the -618- +71 region is available and sufficient for further establishment of mechanisms of NFAT-triggered FasL expression in CORT-treated Leydig cells.
The data presented in this paper firstly suggested that activity of FasL promoter (at -689 bp sequences) was enhanced in CORT-treated mLTC. To establish the minimal function region on FasL promoter which is interaction with NFAT, we synthesized a series of 5' deletion constructs and tested their transcriptional activities in response to CORT treatment. It was firstly found the presence of a high active site situated between -201- +71 (Fig. 8). Our present data showed that there are two NFAT binding sites between -201-+71 region (with total 272 bp) and only one NFAT binding site between -167-+71 region (with total 238 bp). The 272 bp showed the maximal activation in whole FasL promotor sequences. Latinis et al. reported that the binding of NFAT to the GGAAA site on FasL active core sequence is critical for triggering FasL promoter activity . So this specific short sequence was selected as mutated site in present experiment. It was found that the mutated sequence significantly resulted in an inhibition of FasL promoter activity following the nucleotides sequence was mutated. Finally, co-transfection experiments with the NFAT expression vector and FasL promoter with report gene further showed that NFAT enhanced transcriptional activity of FasL promoter by interaction with its -272 bp DNA sequence, thereby regulating FasL promoter activity in CORT-treated Leydig cells. In addition, mutation at -272 bp DNA sequence also resulted in an inhibition of transcriptional activity of FasL promoter in co-transfection experiments. Furthermore, the ChIP result further confirms that NFAT directly bind to FasL promoter sequence in vivo.
Our present findings provide further insight into the mechanisms involved on the regulation of the FasL expression in response to CORT treatment in Leydig cells. In summary, the mechanisms of transcriptional regulation of FasL expression in CORT-treated mLTC-1 is an activation on transcription factor NFAT. The active transcription factor interact with specific NFAT target genes in FasL promoter sequence at -201 to +71 region, thereby regulating FasL expression.
Cells and reagents
Cell line mLTC-1 (mouse Leydig tumor cell) was purchased from American Type Culture Collection (Cat. No. CRL-2065). CORT was purchased from Sigma Chemical Co. QuickChange Site-Directed Mutagenesis Kit was purchased from Stratagene Inc (La Jolla. CA, Cat. No.200518). Qiagen Plasmid Maxiprep Kit was obtained from Qiagen (Santa Clarita, CA, Cat. No.12162) The Dual-Luciferase Reporter Assay System was purchased from Promega Co (Madson, WI, Cat. No.E1910). The Fluo-3/AM was purchased from Sigma Co. Specific antibody for FasL was obtained from Oncogene (Cambridge, MA, Cat. No. PC78). The anti-NFAT2 was obstained from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, Cat. No. SC-1149).
Isolation of primary rat Leydig cells
Adult Leydig cells were isolated from the 90-day-old rats according to the procedure of Sriraman et al. , which is a modification of the procedure described by Klinefelter et al. . The decapsulated testes were subjected to collagenase digestion in a 50 mL plastic tube containing 10 mL medium with collagenase (600 units) and DNase (750 units). The tubes were placed in a shaking water bath and constantly agitated (50 times/min) at 34°C for 15–20 min until the seminiferous tubules were separated. The enzyme action was terminated by adding excess medium. The tubules were allowed to settle by gravity and the medium, consisting of interstitial cells, was aspirated and filtered through a 100 μm nylon mesh. The filtrate was centrifuged at 250 × g for 10 min at 25°C, which yielded a crude interstitial pellet. The pellet obtained was suspended in 35 mL 55% isotonic Percoll with 750 units DNase in Oakridge tubes. The tubes were centrifuged at 20 000 × g for 1 h at 4°C. Percoll fractions corresponding to densities of 1.070–1.090 g/mL were collected and the cells present in this fraction were pelleted down by centrifugation at 250 × g for 10 min at 25°C after diluting it with 3–4 volumes of the medium. The purities of the isolated cell fractions were evaluated by histochemical staining for 3β-hydroxysteroid dehydrogenase activity, with 0.4 nm etiocholanolone as the steroid substrate . The enrichment of the Leydig cells was up to a purity of 85% on average.
RNA isolation and RT-PCR
Total RNA was prepared from mLTC-1 cells using the Trizol Reagent (Gibco, Cat. No.15596-026) according to the manufacturer's instruction. First strand cDNA synthesis was performed using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, Cat. No. A3500) in a reaction using 2 μg of total RNA primed with random hexamers in a total reaction volume of 20 μl. Following first strand synthesis, 10% of the reaction volume was used as a DNA template for amplification by polymerase chain reaction (PCR). For detection of NFAT2, the forward and reverse primers were 5'-GCCCTGACCACCGATAGCAC-3' and 5'-GCTGCCTTCCGTCTCATAGTG-3', respectively. PCR was performed for 30–32 cycles with denaturing at 94°C for 1 min, annealing at 58°C for 1 min and extension at 72°C for 1 min, in a GeneAmp PCR System 9600 (PerkinElmer, Norwalk, CT, USA). For detection of FasL, specific oligonucleotide primers were used as follows: forward primers; 5'-ATTGGCACCATCTTTACT-3' and reverse primers; 5'-CCTTAGAATCTGTTTGTCC-3'). PCR was performed for 28–30 cycles with denaturing at 95°C for 50s, annealing at 58°C for 45s and extension at 72°C for 50s. The signal intensities of the amplified fragments of NFAT2 and FasL were normalized to β-actin using a densitometer. Amplified PCR products were separated by agarose gel electrophoresis and detected by ethidium bromide staining. For amplification of NFAT2, the forward and reverse primers were 5'- CCG GAA TTC GAC ATG ACG GGG CTG GAG CAG GAC CCG GAG -3'and 5'- CGC GGA TCC TCG TAA ATA AAA CAC CCT AGA AAG TTG AAA-3', respectively. PCR was performed for 34 cycles with denaturing at 94°C for 50s, annealing at 60°C for 45s and extension at 72°C for 120s. The NFAT2 cDNA was purified by QIAquick PCR Purification Kit.
Western blot analysis
mLTC-1 and primary rat Leydig cells were lysed in Ripa buffer (1% NP-40, 0.1% SDS, 0.5% DOC, 150 mM NaCl, 10 mM Tris-HCl, and PMSF mixture) at 4°C for 30 min. Protein concentrations were determined by the Bradford dye-binding assay using bovine serum albumin as a standard. Aliquots of cell extracts containing equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis on 8% gels using the Laemmli buffering system, then proteins were transferred to Immuno-Blot polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA) and blocked by rocking for 1 h at room temperature in blocking buffer (Tris-buffered saline with 0.1% Tween 20 and 5% nonfat dry milk). Blots were exposed to primary antibodies for 1 h at room temperature, multiply washed with Tris-buffered saline with 0.1% Tween 20 (TBST), treated with secondary antibody (HRP-conjugated) for 1 h, and followed by a final series of washed with TBST. Primary (goat polyclonal anti-NFAT2 or rabbit polyclonal anti-FasL) and secondary antibodies were prepared in blocking buffer. Signals were detected with an Enhanced Chemiluminescence kit (ECL Pierce, Rockford, IL) and analyzed using Adobe Photoshop 6.0 software.
The following sequences specific for mouse NFAT2 gene were used: NFAT2 siRNA394 (Sense: 5'-GGA GGU GGA AGA CGU ACU UTT-3'; Antisense: 5'-AAG UAC GUC UUC CAC CUC CTT-3') and NFAT2 siRNA1232 (Sense: 5'-CCG UCA CAU UCU GGU CCA UTT-3'; Antisense: AUG GAC CAG AAU GUG ACG GTT-3'). The Lipofectamine 2000 was used to deliver siRNA (100 pmol) into cultured mLTC-1 cells (5 × 104) in 6-well plates according to the manufacturer's protocol. The double-strand scrambled siRNA (5'-UUC UCC GAA CGU GUC ACG UTT-3') were used as negative control. The cultures were incubated for six hours and then washed and incubated in fresh medium. All siRNA were obtained from Shanghai Genepharma Co. Inc. (Shanghai, China).
Genomic DNA was isolated from C57BL6 using DNAeasy kit (Qiagen, Valencia, CA, Cat. No.69504). A 689 bp PCR fragment corresponding to the promoter region of FasL (-618- +71) was generated using the upstream primer 5'-CGGGGTACCGTACCTCAGTTTTCATCTGGTGACCAGAAG-3' and the downstream primer 5'-CCCAAGCTTGCACCCAGCCCCAGGAAA GG-3' in a PCR using platinum Pfx high fidelity polymerase (Invitrogen, Cat.No. 11708013) and 50 ng of genomic DNA template. The resultant 689 bp fragment was gel-purified, and cloned into pGEM ®-T Easy vector (Promega, Cat.No. A1360) and sequenced for orientation and fidelity. This plasmid (pGEM-689pCD95L) was served as the source of the insert for further plasmid constructions. To make the -618 to +71 luciferase reporter plasmid, the 689 bp insert was excised with Kpn I and Hind III and ligated into the Kpn I/Hind III site of pGL3 Basic luciferase vector (Promega, Cat.No.E1751). To make the 5'truncation mutants, shorter fragments were generated using new upstream primers, and the common downstream primer was used to make the -618 to +71 insert. For the -258 to +71 fragment, the upstream primer 5'-CGGGGTACCCAGGCAAGCCTGGTTTACCAGC C-3' and the common downstream were used. To generate the -201 to +71 fragment, the upstream primer 5'-CGGGGTACCCGAAGACTTGTCGTCAGAA ATTTC-3' was used. The -167 to +71 fragment was produced using 5'-CGGGGTACCCTTCCTGGGGTT GCTGTGAGC- 3'. The -138 to +71 fragment was produced using 5'-CGGGGTACCGCTTCTCAGCTTC A ATGCAAG-3'. The -67 to +71 fragment was produced by using the upstream primer 5' -CCCAAGCTT GCACCCAGCCCCAGGAAAGG-3'. The resultant fragment were subcloned into the polylinker site of pGEM-T vector and sequenced for orientation and fidelity. Luciferase reporter constructs were produced by excising the various fragments with Kpn I and Hind III and then subcloning the fragments into the polylinker site of pGL3-basic.
NFAT2 cDNA sequences were digested with EcoRI and BamHI, and ligated into the EcoRI/BamHI site of pEGFP-C1 plasmids to construct the NFAT2-GFP fusion protein expression vector.
Mutant construct was generated by using the QuickChange Site-Directed Mutagenesis Kit. The mutation was verified by DNA sequencing. Mutant of the NFAT site in FasL promoter (FasL-P272m) were synthesized by Sangon Co.: 5'-GTCGTCAGAAATTTCTGGGAATC AACTTCCTGGGGTTGCTGTGAG -3'.
Transient transfections and luciferase reporter assays
For transfection analysis, luciferase assays were performed according to the manufacturer's instruction using the Lipofectamine™ 2000 reagent (Invitrogen Co. Cat. No.11668-019). Briefly, the cells were seeded into 24-well plates at a density of 5 × 105 cells/well and incubated at 37°C overnight. Cells were then placed in DMEM with 10 % fetal bovine serum containing 1 μg of luciferase plasmid, 0.1 μg of pRL SV40 reporter plasmid, and 2 μg of Lipofectamine™ 2000. Thirty-six hours following transfection, the cells were treated with 100 nM CORT. Following the treatment, the Dual Luciferase Assay was performed by lysing the cells in Passive Lysis Buffer, and reading the relative light units of one-fifth the lysate with both the firefly substrate and the renilla substrate using a luminometer (Monolight 2010, Analytical Luminescence Laboratory, SanDiego, CA). Each transfection was performed in triplicate and in a minimum of three independent experiments.
Confocal microscopy analysis of NFAT2-GFP nuclear translocation
mLTC-1 were transiently transfected with NFAT2-GPF expression vector. At 36 h after transfection, cells were treated with 100 nM CORT, or 100 nM CORT plus 100 ng/ml CsA for 12 h. NFAT2-GFP expression and localization was monitored by Confocal microscopy.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was performed according to the manufacturer's protocol. mLTC, cultivated in DMEM containing 10% bovine calf serum, were incubated with 100 nM CORT for 12 h, cross-linked by formaldehyde for 10 minutes at 37°C. The reaction was stopped with 0.125 M glycine. Cells were washed using cold PBS containing protease inhibitors. DNA were sheared by sonicate lysate to lengths between 200–1000 bp. Cell samples were centrifuged for 10 minutes at 13,000 rpm at 4°C and supernatant stored at -80°C as chromatin extracts. For chip analysis, pre-cleared the sample with salmon sperm DNA/protein agarose for 30 min at 4°C. Lysates were subjected to immunoprecipitation with anti-NFAT2 antibodies (Santa Cruz Biotechnology) and non-specific IgG (Santa Cruz) were added individually and incubated at 4°C overnight with rotation. Bound and input chromatin samples were placed in 0.5% (wt/vol) SDS and incubated at 65°C for 4 hours to reverse the formaldehyde cross-linking. DNA was further purified by phenol-chloroform extraction and ethanol precipitated using glycogen as an inert carrier. Of the obtained DNA, 2 μl was used in a 20-μl PCR reaction (Taq DNA Polymerase; Qiagen) using the following primers: FasL-F, 5'-CAGTTAGCACAGAGACGCCAAT-3'; FasL-R, 5' -TGCTTCTCTGTGAGACACCCAC-3'.
mLTC-1 cells were treated with 100 nM CORT or 100 nM CORT plus 100 ng/ml CsA for 12 h followed by detection of apoptosis. The annexin-V was used to assess apoptosis. For the annexin-V assay, the mLTC-1 cells were incubated with 10 μL propidium iodide (PI) and 5 μL FITC-annexin-V (BD Biosciences, Franklin Lakes, NJ, USA) at room temperature for 15 min. Then, the cells were analyzed on FACS. Annexin-V binds to those cells that express phosphotidylserine on the outer layer of the cell membrane, and PI stains the cellular DNA of cells with a compromised cell membrane. This allows for the discrimination between live cells (unstained with either fluorochrome) from apoptotic cells (stained only with annexin-V) and necrotic cells (stained with both annexin-V and PI).
All experiments were performed in triplicate. The Student's t-test was used to determine the statistical significance of the data obtained. P < 0.05 or P < 0.01 was taken to represent a statistically significant difference between group mean.
We thank Dr. Matthew P. Hardy in the Rockefeller University and Population Councial Center for Biomedical Research for critical comments on the manuscript. He died before the completion of this manuscript, and we dedicate this study to him. This work was supported in part by grants 30570681 and 214503 from National Natural Science Foundation of China and Shanghai Municipal Education Foundation, China, respectively.
- Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992, 148: 1274-9.PubMed
- Rouvier E, Luciani MF, Golstein P: Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993, 177: 195-200. 10.1084/jem.177.1.195.View ArticlePubMed
- Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993, 75: 1169-1178. 10.1016/0092-8674(93)90326-L.View ArticlePubMed
- Arase H, Arase N, Saito T: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med. 1995, 181: 1235-1238. 10.1084/jem.181.3.1235.View ArticlePubMed
- Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature. 1995, 377: 630-632. 10.1038/377630a0.View ArticlePubMed
- Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995, 270: 1189-1192. 10.1126/science.270.5239.1189.View ArticlePubMed
- Gao HB, Tong MH, Hu YQ, You HY, Guo QS, Ge RS, Hardy MP: Mechanisms of glucocorticoid-induced Leydig cell apoptosis. Mol Cell Endocrinol. 2003, 199: 153-163. 10.1016/S0303-7207(02)00290-3.View ArticlePubMed
- Gao HB, Tong MH, Hu YQ, Guo QS, Ge RS, Hardy MP: Glucocorticoid induces apoptosis in rat leydig cells. Endocrinology. 2002, 143: 130-138. 10.1210/en.143.1.130.View ArticlePubMed
- Gao HB, Shan LX, Monder C, Hardy MP: Suppression of endogenous corticosterone levels in vivo increases the steroidogenic capacity of purified rat Leydig cells in vitro. Endocrinology. 1996, 137: 1714-1718. 10.1210/en.137.5.1714.PubMed
- Li-Weber M, Laur O, Krammer PH: Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T cell stimulation. Eur J Immunol. 1999, 29: 3017-3027. 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R.View ArticlePubMed
- Chai WR, Qian Wang, Gao HB: NFAT2 is implicated in cortic osterone-induced rat Leydig cell apoptosis. Asian J Androl. 2007, 9 (5): 623-33. 10.1111/j.1745-7262.2007.00257.x.View ArticlePubMed
- Sriraman V, Rao VS, Sairam MR, Rao AJ: Effect of deprival of LH on Leydig cell proliferation: involvement of PCNA, cyclin D3 and IGF-I. Mol Cell Endocrinol. 2000, 162: 113-20. 10.1016/S0303-7207(00)00201-X.View ArticlePubMed
- Klinefelter GR, Hall PF, Ewing LL: Effect of luteinizing hormone deprivation in situ on steroidogenesis of rat Leydig cells purified by a multistep procedure. Biol Reprod. 1987, 36: 769-83. 10.1095/biolreprod36.3.769.View ArticlePubMed
- Payne AH, Downing JR, Wong KL: Luteinizing hormone receptor and testosterone synthesis in two distinct populations of Leydig cells. Endocrinology. 1980, 106: 1424-9.View ArticlePubMed
- Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas(CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 1995, 373: 441-444. 10.1038/373441a0.View ArticlePubMed
- Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995, 181: 71-77. 10.1084/jem.181.1.71.View ArticlePubMed
- Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1(Fas/CD95). Nature. 1995, 373: 438-441. 10.1038/373438a0.View ArticlePubMed
- Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373: 444-448. 10.1038/373444a0.
- Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J Exp Med. 1989, 169: 1747-1756. 10.1084/jem.169.5.1747.View ArticlePubMed
- Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/Apo-1 contains sequence motif related to the death domain. J Biol Chem. 1995, 270: 7795-7798. 10.1074/jbc.270.14.7795.View ArticlePubMed
- Chinnaiyan AM, Rourke KO, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interaction with the decth domain of Fas and initiates apoptosis. Cell. 1995, 81: 505-512. 10.1016/0092-8674(95)90071-3.View ArticlePubMed
- Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997, 15: 707-747. 10.1146/annurev.immunol.15.1.707.View ArticlePubMed
- Crabtree GR, Olson EN: NFAT signaling: choreographing the social lives of cells. Cell. 2002, 109 (Suppl): S67-79. 10.1016/S0092-8674(02)00699-2.View ArticlePubMed
- Serfling E, Berberich-Siebelt F, Chuvpilo S, Jankevics E, Klein-Hessling S, Twardzik T, Avots A: The role of NF-AT transcription factors in T cell activation and differentiation. Biochim Biophys Acta. 2000, 1498: 1-18. 10.1016/S0167-4889(00)00082-3.View ArticlePubMed
- Garcia-Cozar FJ, Okamura H, Aramburu JF, Shaw KT, Pelletier L, Showalter R, Villafrance E, Rao A: Two-site interaction of nuclear factor of activated T cells with activated calcineurin. J Biol Chem. 1998, 273: 23877-23883. 10.1074/jbc.273.37.23877.View ArticlePubMed
- Garcia-Rodriguez C, Rao A: Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivatiors p300/CREB-binding protein (CBP). J Exp Med. 1998, 187: 2031-2036. 10.1084/jem.187.12.2031.PubMed CentralView ArticlePubMed
- Yoo YG, Lee MO: Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor. J Biol Chem. 2004, 279: 36242-36249. 10.1074/jbc.M401290200.View ArticlePubMed
- Feske S, Draeger R, Peter HH, Eichmann K, Rao A: The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J Immunol. 2000, 165: 297-305.View ArticlePubMed
- Horsley V, Pavlath GK: NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol. 2002, 156: 771-774. 10.1083/jcb.200111073.PubMed CentralView ArticlePubMed
- Graef IA, Wang F, Charron F, Chen L, Neilson J, Tessier-Lavigne M, Crabtree GR: Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell. 2003, 113: 657-670. 10.1016/S0092-8674(03)00390-8.View ArticlePubMed
- Gonzalez Bosc LV, Wilkerson MK, Bradley KN, Eckman DM, Hill-Eubanks DC, Nelson MT: Intraluminal pressure is a stimulus for NFATc3 nuclear accumulation: role of calcium, endothelium-derived nitric oxide, and cGMP-dependent protein kinase. J Biol Chem. 2004, 279: 10702-10709. 10.1074/jbc.M312920200.View ArticlePubMed
- Hernandez GL, O Volpert V, Iniguez MA, Lorenzo E, Martinez-Martinez S, Grau R, Fresno M, Redondo JM: Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A:roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001, 193: 607-620. 10.1084/jem.193.5.607.PubMed CentralView ArticlePubMed
- Graef IA, Chen F, Chen L, Kuo A, Crabtree GR: Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell. 2001, 105: 863-875. 10.1016/S0092-8674(01)00396-8.View ArticlePubMed
- Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, Hoey T, Mickanin C, Baldwin HS, Glimcher LH: The transcription factor NF-ATc is essential for cardiac valve formation. Nature. 1998, 392: 186-190. 10.1038/32426.View ArticlePubMed
- Jie Zhang, Kathleen Miranda, Bei-Yang Ma, Alan Fine: Molecular characterization of the mouse Fas ligand promoter in airway epithelial cell. Biochimica et Biophysica Acta. 2000, 1490: 291-301.View Article
- Latinis KM, Norian LA, Eliason SL, Koretaky GA: Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J Biol Chem. 1997, 272: 31427-31434. 10.1074/jbc.272.50.31427.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.